EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, SCYNEXIS's enterprise value is $-2.7 Mil.
SCYNEXIS's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $140.1 Mil. Therefore, SCYNEXIS's EV-to-Revenue for today is -0.02.
The historical rank and industry rank for SCYNEXIS's EV-to-Revenue or its related term are showing as below:
SCYX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -81.5 Med: 28 Max: 1356.88
Current: -0.02
During the past 12 years, the highest EV-to-Revenue of SCYNEXIS was 1356.88. The lowest was -81.50. And the median was 28.00.
SCYX's EV-to-Revenue is ranked worse than 100% of 1025
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs SCYX: -0.02
As of today (2024-04-25), SCYNEXIS's stock price is $1.47.
SCYNEXIS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.82. Therefore, SCYNEXIS's PS Ratio for today is 0.52.
SCYNEXIS EV-to-Revenue Historical Data
The historical data trend for SCYNEXIS's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SCYNEXIS's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's EV-to-Revenue falls into.
SCYNEXIS's current Enterprise Value is $-2.7 Mil.
SCYNEXIS's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $140.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS's share price for today is $1.47.
SCYNEXIS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.82.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of SCYNEXIS's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your 